Z Gastroenterol 2020; 58(08): e174-e175
DOI: 10.1055/s-0040-1716199
BEST Abstracts DGVS: Publikationen

The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries

Autoren

  • J Schattenberg

    1   I. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz, Mainz, Deutschland

  • P Newsome

    2   University of Birmingham, Birmingham, Vereinigtes Königreich

  • L Serfaty

    3   Hôpitaux Universitaires de Strasbourg, Strasbourg, Frankreich

  • A Aghemo

    4   Humanitas University and Humanitas Research Hospital IRCCS, Pieve Emanuele, Mailand, Italien

  • S Augustin

    5   Hospital Universitari Vall d’Hebron - Institut de Recerca, Barcelona, Spanien

  • E Tsochatzis

    6   UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, Vereinigtes Königreich

  • A Canbay

    7   Universitätsklinikum Magdeburg, Magdeburg, Deutschland

  • V de Ledinghen

    8   Centre Hospitalier Universitaire Bordeaux, Bordeaux, Frankreich

  • E Bugianesi

    9   University of Torino, Department of Medical Sciences, Turin, Italien

  • M Romero-Gomez

    10   Virgen del Rocío University Hospital, Sevilla, Spanien

  • S Ryder

    11   Nottingham University Hospitals, Nottingham, Vereinigtes Königreich

  • H Bantel

    12   Klinik für Gastroenterologie, Hepatologie und Endokrinologie; Medizinische Hochschule Hannover, Hannover, Deutschland

  • J Boursier

    13   Angers University Hospital, Angers, Frankreich

  • S Petta

    14   Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italien

  • J Crespo

    15   Hospital Universitario Marqués de Valdecilla, Santander, Spanien

  • L Castera

    16   Université Paris-7, Department of Hepatology, Hôpital Beaujon, Paris, Frankreich

  • V Leroy

    17   Centre Hospitalier Universitaire de Grenoble, Grenoble, Frankreich

  • C Le Pen

    18   University Paris-Dauphine, Paris, Frankreich

  • F-U Fricke

    19   Technische Hochschule Nürnberg, Nürnberg, Deutschland

  • R Elliott

    20   University of Manchester, Manchester, Vereinigtes Königreich

  • V Atella

    21   University Rome Tor Vergata, Rom, Italien

  • J Mestre-Ferrandiz

    22   Independent Economics Consultant, Madrid, Spanien

  • L Floros

    23   PHMR Limited, London, Vereinigtes Königreich

  • A Torbica

    24   Bocconi University, Mailand, Italien

  • A Morgan

    25   Deloitte, Canberra, Australien

  • S Hartmanis

    26   Deloitte, Victoria, Australien

  • A Trylesinki

    27   Intercept Pharmaceuticals, London, Vereinigtes Königreich

  • S Cure

    27   Intercept Pharmaceuticals, London, Vereinigtes Königreich

  • E Stirzaker

    25   Deloitte, Canberra, Australien

  • S Vasudevan

    26   Deloitte, Victoria, Australien

  • L Pezzulo

    26   Deloitte, Victoria, Australien

  • V Ratziu

    28   Sorbonne Université, Hôpital Pitié - Salpêtrière, Paris, Frankreich
Weitere Informationen
Auch verfügbar auf
 
 

Background NASH is a chronic disease which can progress to end-stage liver disease (ESLD) if left untreated. There is a high risk of particularly rapid progression to ESLD in people with advanced liver fibrosis due to NASH, few of whom are diagnosed and under treater care in the EU5 countries. This study aims to estimate the prevalence of NASH and the socioeconomic burden associated with its treatment in the EU5 countries during 2018.

Methods The burden of NASH per country was estimated using cost-of-illness methodology applying a prevalence approach to estimate the number of adults with NASH in a base period, and the economic and wellbeing costs attributable to diagnosed NASH in that period. Wellbeing costs were estimated using the WHO burden of disease methodology, which includes societal wellbeing measures e.g. disability-adjusted life years (DALYs). The analysis was based on literature review and consultations with clinical experts, health economists and patient groups to reach consensus. Epidemiological data were derived from modelling studies (upper and lower bound). Resource-use estimates were based on literature and expert opinion to reflect current clinical practice. Unit costs were sourced from the literature and local fee schedules.

Results In the EU5 in 2018, only a small subset of adults living with any-stage NASH were diagnosed due to the low probability of being diagnosed at  <  F3 stage (where there is usually minimal symptomatology). Of the 0.9 - 2.0 million adults estimated to have advanced liver fibrosis due to NASH, only 37.8 - 39.1% were diagnosed. Direct costs due to NASH were estimated at €619 - 1,292 million/year; 95% of these costs were incurred from the diagnosis and monitoring of patients with advanced liver fibrosis due to NASH. Adults with NASH experienced between 311,944 and 660,451 DALYs. Total wellbeing costs ranged from €41,536 to 90,379 million, primarily driven by the high rate of premature mortality in patients with NASH.

Conclusions This study provides a realistic estimate of the number of adults diagnosed with any-stage NASH and under treater care in the EU5 in 2018. Prevention of progression to ESLD and appropriate management of adult NASH patients could result in reduced economic impact and improvements in wellbeing.


Publikationsverlauf

Artikel online veröffentlicht:
08. September 2020

© Georg Thieme Verlag KG
Stuttgart · New York